EUCTR2010-023230-22-GB进行中（未招募）1 期
A phase II trial to assess the safety, immunological activity of Trovax plus Pemetrexed/ Cisplatin in patients with malignant pleural mesothelioma. - SKOPOS Trial
Velindre NHS Trust0 个研究点目标入组 29 人开始时间: 2011年3月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Signed and dated written informed consent obtained from the patient in accordance with the local regulations
- •Locally advanced or metastatic, histologically or cytologically proven MPM
- •Aged 18 years or over
- •WHO performance status 0-1 (Appendix I)
- •Life expectancy > 6months
- •Haemoglobin = 12 g/dl, total white cell count = 3 x 10^9/L, neutrophil count > 1.5 x 10^9/L, lymphocyte count =1 x 10^9/L, monocyte count <0.8 x 10^9/L platelet count >100 x 10^9/L and <400 x 10^9/L. Blood transfusion is allowed.
- •Adequate renal function: Creatinine = 50 mL/min as measured by EDTA or 60mL/min as measured by the Cockroft-Gault formula
- •Adequate liver function: ALT, AST and bilirubin < 2 times the upper limit of normal
- •At least four weeks from any previous therapy including surgery, or radiotherapy
- •Able to comply with the protocol
- •Women must be either post-menopausal, or rendered surgically sterile or, if of child-bearing potential, must have a negative pregnancy test prior to trial entry. Two reliable forms of contraception (oral contraception and a barrier method) must be used by all participants while they are being treated with the TroVax® vaccine. Females must continue to use this level of contraception for 3 months following the last trial treatment, and male patients must continue for 1 month.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •*Serious infections within the 28 days prior to entry to the trial.
- •*Prior TroVax® treatment
- •*Previous chemotherapy for MPM
- •*Major surgery or radiation therapy completed = 4 weeks prior to enrolment
- •*Prior radiopharmaceuticals (strontium, samarium) less than 8 weeks prior to enrolment
- •*Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days
- •*History of prior malignant disease unless patient has been disease-free for at least 3 years or the tumour was a non-melanoma skin cancer or early cervical cancer
- •*Autoimmune disease including systemic Lupus Erythematosis, Grave’s disease, Hashimoto’s thyroiditis, multiple sclerosis, insulin dependent diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease
- •*Clinical significant cardiac failure or a measured ejection fraction of <40%
- •*Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the patient inappropriate for entry into this study.
- •*Chronic oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency, or other immunosuppressive agents. Dexamethasone is allowed as part of trial treatment.
- •*Cerebral metastases
- •*History of allergic response to previous vaccine vaccinations
- •*Known allergy to egg proteins
- •*Known to test positive for HIV or hepatitis B or C
- •*Pregnancy or lactation
- •*Prior history of organ transplantation
研究者
相似试验
招募中
不适用
TaMoVaC IIPACTR201211000435126Swedish Institute for Infectious Disease Control198
已完成
2 期
A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adultsJPRN-jRCT2071210086Inoguchi Akihiro80
进行中（未招募）
1 期
Safety and immunogenicity of RNA-based vaccines against SARS-CoV-2 variants in healthy participantsProtection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-003458-22-DEBioNTech SE1,470
已完成
1 期
A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults and elderly subjectsPrevention of COVID-19JPRN-jRCT2071200110Inoguchi Akihiro152
进行中（未招募）
不适用
Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine. - LSA3-trialP. falciparum infection (malaria)EUCTR2006-001743-66-NLINSTITUT PASTEUR, Biomedical Parasitology Unit